Literature DB >> 28919996

MEK inhibition and immune responses in advanced melanoma.

Reinhard Dummer1, Egle Ramelyte1, Sabrina Schindler1, Olaf Thürigen2, Mitchell P Levesque1, Peter Koelblinger1,3.   

Abstract

phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy improved the outcome of binimetinib therapy. We discuss this finding in the context of in vitro and in vivo effects of MEK inhibition on immuno-critical pathways and interactions.

Entities:  

Keywords:  BRAF mutation; MEK inhibitors; MEK kinase pathway; Melanoma; NRAS mutation; immunogenicity; immunotherapy

Year:  2017        PMID： 28919996      PMCID： PMC5593717          DOI： 10.1080/2162402X.2017.1335843

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  31 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.

Authors:  Marie C Zipser; Ossia M Eichhoff; Daniel S Widmer; Natalie C Schlegel; Nicola L Schoenewolf; Darrin Stuart; Weihua Liu; Humphrey Gardner; Paul D Smith; Paolo Nuciforo; Reinhard Dummer; Keith S Hoek
Journal:  Pigment Cell Melanoma Res       Date:  2011-01-12       Impact factor: 4.693

3.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

4.  The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Authors:  Xiaofeng Jiang; Jun Zhou; Anita Giobbie-Hurder; Jennifer Wargo; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

5.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Authors:  Elliott J Brea; Claire Y Oh; Eusebio Manchado; Sadna Budhu; Ron S Gejman; George Mo; Patrizia Mondello; James E Han; Casey A Jarvis; David Ulmert; Qing Xiang; Aaron Y Chang; Ralph J Garippa; Taha Merghoub; Jedd D Wolchok; Neal Rosen; Scott W Lowe; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2016-09-28       Impact factor: 11.151

6.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Authors:  Peter J R Ebert; Jeanne Cheung; Yagai Yang; Erin McNamara; Rebecca Hong; Marina Moskalenko; Stephen E Gould; Heather Maecker; Bryan A Irving; Jeong M Kim; Marcia Belvin; Ira Mellman
Journal:  Immunity       Date:  2016-03-02       Impact factor: 31.745

7.  The Erk2 MAPK regulates CD8 T cell proliferation and survival.

Authors:  Warren N D'Souza; Chiung-Fang Chang; April M Fischer; Manqing Li; Stephen M Hedrick
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

9.  Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Authors:  Marieke I G Raaijmakers; Daniel S Widmer; Apurva Narechania; Ossia Eichhoff; Sandra N Freiberger; Judith Wenzina; Phil F Cheng; Daniela Mihic-Probst; Rob Desalle; Reinhard Dummer; Mitchell P Levesque
Journal:  Oncotarget       Date:  2016-11-22

10.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307
View more
  8 in total

Review 1.  Immunological effects of BRAF+MEK inhibition.

Authors:  Paolo A Ascierto; Reinhard Dummer
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 2.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

Review 3.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

4.  Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.

Authors:  Mai Q Nguyen; Jessica L F Teh; Timothy J Purwin; Inna Chervoneva; Michael A Davies; Katherine L Nathanson; Phil F Cheng; Mitchell P Levesque; Reinhard Dummer; Andrew E Aplin
Journal:  J Invest Dermatol       Date:  2020-05-07       Impact factor: 8.551

5.  Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.

Authors:  Reinhard Dummer; Simone M Goldinger; Alexandra Valeska Matter; Sara Micaletto; Ursula Urner-Bloch
Journal:  Oncologist       Date:  2020-09-21

6.  Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.

Authors:  David A Close; John M Kirkwood; Ronald J Fecek; Walter J Storkus; Paul A Johnston
Journal:  SLAS Discov       Date:  2020-11-18       Impact factor: 3.341

7.  Targeted treatment of advanced NRAS-mutated melanoma.

Authors:  Peter Koelblinger; Reinhard Dummer
Journal:  Oncotarget       Date:  2017-09-29

Review 8.  Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.

Authors:  Ryuhjin Ahn; Josie Ursini-Siegel
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.